WO2006002255A3 - A pharmaceutical formulation of balaglitazone - Google Patents

A pharmaceutical formulation of balaglitazone Download PDF

Info

Publication number
WO2006002255A3
WO2006002255A3 PCT/US2005/022094 US2005022094W WO2006002255A3 WO 2006002255 A3 WO2006002255 A3 WO 2006002255A3 US 2005022094 W US2005022094 W US 2005022094W WO 2006002255 A3 WO2006002255 A3 WO 2006002255A3
Authority
WO
WIPO (PCT)
Prior art keywords
balaglitazone
pharmaceutical formulation
formulation
quinazolin
ylmethoxy
Prior art date
Application number
PCT/US2005/022094
Other languages
French (fr)
Other versions
WO2006002255A2 (en
Inventor
Carsten Ravn
Stella Rudkaer Rasmussen
Original Assignee
Reddys Lab Ltd Dr
Reddys Lab Inc Dr
Carsten Ravn
Stella Rudkaer Rasmussen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr, Reddys Lab Inc Dr, Carsten Ravn, Stella Rudkaer Rasmussen filed Critical Reddys Lab Ltd Dr
Publication of WO2006002255A2 publication Critical patent/WO2006002255A2/en
Publication of WO2006002255A3 publication Critical patent/WO2006002255A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A formulation of 5-[4-(3-Methyl-4-oxo-3,4-dihydro-quinazolin-2-ylmethoxy)-benzyl]-thiazolidine-2,4-dione and/or pharmaceutically acceptable salts thereof is provided.
PCT/US2005/022094 2004-06-23 2005-06-22 A pharmaceutical formulation of balaglitazone WO2006002255A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400977 2004-06-23
DKPA200400977 2004-06-23

Publications (2)

Publication Number Publication Date
WO2006002255A2 WO2006002255A2 (en) 2006-01-05
WO2006002255A3 true WO2006002255A3 (en) 2006-11-09

Family

ID=35782324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/022094 WO2006002255A2 (en) 2004-06-23 2005-06-22 A pharmaceutical formulation of balaglitazone

Country Status (1)

Country Link
WO (1) WO2006002255A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352430C (en) 1998-12-01 2008-11-18 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO2000032191A1 (en) * 1998-12-01 2000-06-08 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO2000032191A1 (en) * 1998-12-01 2000-06-08 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation

Also Published As

Publication number Publication date
WO2006002255A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
DZ3316A1 (en) Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP1884242A4 (en) Pharmaceutical composition
TW200745099A (en) Optically active thiazolidinedione derivatives
HK1111888A1 (en) Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]
MXPA01010821A (en) Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
WO2009047565A3 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
EP1902713A4 (en) Pharmaceutical composition containing thiazolidinedione compound
WO2006002255A3 (en) A pharmaceutical formulation of balaglitazone
IL154724A0 (en) The hydrochloride salt of 5-[4- [2- (n-methyl-n- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione
WO2005113526A3 (en) Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
EA200300234A1 (en) TARTRAT SALTS DERIVATIVE TIAZOLIDINDIONA
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
WO2007130064A8 (en) 2-n-(5-[[4-(2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione) butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2005107809A8 (en) Antimycobacterial pharmaceutical composition comprising an antitubercular drug
NO20025882D0 (en) 5- (4- (2- (N-methyl-N- (2-pyridyl) amino) ethoxy) benzyl) -thiazolidine-2,4-dione hydriodide as a pharmaceutical agent
WO2002028857A8 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
AU2001284285A1 (en) A thiazolidinedione derivative and its use as antidiabetic
AU2003271635A1 (en) Novel modification of the compound 4-hydroxy-2-methyl-n-(5-methyl-2-thiazolyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide in the form of a crystalline acetic acid solvate and use thereof as a medicament
CY1107767T1 (en) THIAZOLIDINODIONI PRODUCER AND USE OF IT AS ANTIBIOTIC
AU2002343050A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
WO2004089276A3 (en) Thiazolidinedione compounds with hypoglycemic properties
WO2003099337A3 (en) Inclusion complexes of rosiglitazone
NO20030531L (en) Tartrate salts of thiazolidinedione derivatives
AR043924A1 (en) PHARMACEUTICAL FORM THAT INCLUDES ROSIGLITAZONA MALEATE, PREPARATION AND COMPOSITION PROCEDURE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05763644

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05763644

Country of ref document: EP

Kind code of ref document: A2